<DOC>
	<DOC>NCT00954447</DOC>
	<brief_summary>The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.</brief_summary>
	<brief_title>Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: 1. Diabetes type 2, detectable Cpeptide, HbA1c 710% 2. Pretreatment with basal insulin +/ Metformin or/and +/ Pioglitazone 3 Age &gt; 18 years, BMI &lt;= 45 kg/m2 Exclusion criteria: 1. Uncontrolled hyperglycemia during Runin 2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent 3. Liver impairment; gastric surgery; medical history of cancer in last 5 years 4. Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation 5. Unsufficient birth control, pregnancy and nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>